| Literature DB >> 32471930 |
Balakrishnan Ashokka1,2, Arunangshu Chakraborty3, Balavenkat J Subramanian4, Manoj Kumar Karmakar5, Vincent Chan6.
Abstract
The COVID-19 outbreak is on the world. While many countries have imposed general lockdown, emergency services are continuing. Healthcare professionals have been infected with the virulent severe acute respiratory syndrome coronavirus-2 (SARS), which spreads by close contact and aerosols. The anesthesiologist is particularly vulnerable to aerosols while performing intubation and other airway related procedures. Regional anesthesia (RA) minimizes the need for airway manipulation and the risks of cross infection to other patients, and the healthcare personnel. In this context, for prioritizing RA over general anesthesia, wherever possible, a structured algorithmic approach is outlined. The role of percentage saturation of hemoglobin with oxygen (oxygen saturation), blood pressure and early use of point-of-care ultrasound in differential diagnosis and specific management is detailed. The perioperative anesthetic implications of multisystem manifestations of COVID-19, anesthetic management options, the scope of RA and considerations for its safe conduct in operating rooms is described. An outline for safe and rapid training of healthcare personnel, with an Entrustable Professional Activity framework for ascertaining the practice readiness among trained residents for RA in COVID-19, is suggested. These are the authors' experiences gained from the current pandemic and similar SARS, Middle East Respiratory Syndrome and influenza outbreaks in recent past faced by our authors in Singapore, India, Hong Kong and Canada. © American Society of Regional Anesthesia & Pain Medicine 2020. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: education; epidemiology; obstetrics; postoperative complications; regional anesthesia
Mesh:
Year: 2020 PMID: 32471930 PMCID: PMC7362872 DOI: 10.1136/rapm-2020-101541
Source DB: PubMed Journal: Reg Anesth Pain Med ISSN: 1098-7339 Impact factor: 6.288
COVID-19: system wise manifestations and management
| System | Features | Investigation | Treatment | Comments |
| CVS | Palpitation | ECG: diffuse ST-elevations as seen in myopericarditis, nonspecific ST changes, low voltage in the limb leads, and PVCs | Stable patients: guideline-directed medical therapy for heart failure. | SARS Cov-2 uses tissue ACE-2 as receptor. Vascular endothelium and myocardium is affected thus. |
| RS | Cough | CT chest: ground glass opacities- typically bilateral and peripheral, Ground glass opacities consolidations or cordlike opacities, | Oxygen | Increased pulmonary vascular permeability due to increased production of angiotensin II. ARDS with poor lung compliance Non-ARDS inflammatory pulmonary microvascular disease-good lung compliance. |
| Hemat | Leukopenia, Lymphopenia | CAC: | Supportive. | Thrombocytopenia may be caused by reduced production, increased destruction, and increased consumption |
| Renal | Renal injury | Proteinuria | Diuretics, | Effect on kidneys via- |
| CNS | Headache, dizziness, impaired consciousness, acute cerebrovascular problems. | EEG | Supportive | Possibility of non-convulsive status epilepticus should be ruled out in all critical patients with change on mental status. |
| GIT | Anorexia, nausea, vomiting, diarrhea, abdominal pain, bleeding. | Fecal RT-PCR for SARS-COV-2. | Supportive | SARS‐CoV‐2 enters gastrointestinal epithelial cells, and the feces of COVID‐19 patients are potentially infectious. Fecal excretion may persist after sputum becomes negative in patients for 1‐11 days. |
| General | Sepsis, multiorgan failure | RT-PCR from nasopharyngeal swab, CT scan chest, inflammatory markers. | Supportive- systemic | Cytokine release syndrome, cytokine storm causing fever and multiorgan dysfunction |
| Anti viral Therapy | QTc prolongations | ECG | Minimize or use with caution medications that cause further worsening | Assess disease severity |
ACE, angiotensin converting enzyme; aPTT, activated partial thromboplastin time; ARB, angiotensin receptor blocker; ARDS, adult respiratory distress syndrome; CNS, central nervous system; CRP, C reactive protein; CRRT, continuous renal replacement therapy; CSF, cerebrospinal fluid; CVS, cardio vascular system; DIC, disseminated intravascular coagulation; ECG, electrocardiogram; ECMO, extracorporeal membrane oxygenation; EEG, electro encephalogram; GIT, gastrointestinal tract; HCO/MCO, high cut-off/ medium cut-off; IL-6, interleukin-6 ; LDH, lactate dehydrogenase; NIV, non-invasive ventilation; NT Pro-BNP, N terminal pro hormone brain natriuretic peptide; POCUS, point-of-care ultrasound; PT, prothrombin time; PVC, premature ventricular complex; RS, respiratory system; RT-PCR, reverse transcription polymerase chain reaction; SARS-COV-2, severe acute respiratory syndrome coronavirus-2.
Figure 1In situ simulation training layout showing the organization of simulated training in operation room with regional anesthesia set up and infection control practices training. OR, operating room; PAPR, powered air purifying respirators; RA, regional anesthesia.
EPA framework for readiness of trained residents for regional anesthesia in COVID-19
| S no | Domain | EPA |
|
| Infection control | Demonstrates proficiency in donning and doffing of PPE |
|
| Crisis management and infection control | Demonstrates adequacy of resuscitation skills in simulated protected codes |
|
| Communication | Demonstrates effective communication and coordination within protected code teams |
|
| System based management | Demonstrates understanding of pathophysiology and multisystem concerns of COVID-19 |
|
| Regional anesthesia | Demonstrates ability to perform regional anesthesia procedures with remote supervision |
|
| Crisis management and Regional anesthesia | Demonstrates ability to recognize and manage regional anesthesia crisis in simulation |
|
| Critical thinking | Demonstrates appropriate decision-making in patient disposition and safe transfer |
An EPA guided framework for suitability of trained residents in performing regional anesthesia in COVID-19. The domains include regional anesthesia, crisis management, infection preventions and team management skills and critical thinking.
EPA, entrustable professional activity.
Figure 2Showing the systematic approach for considering regional anesthesia in COVID-19 patients. *Hypertension is a common presentation in COVID-19 due to the interactions of the virus with the angiotensin converting enzyme (ACE2): a false normal blood pressure could be early signs of deterioration in a previously hypertensive COVID-19 presentation a.# Sepsis with white cell count > 15x10∧9/L are relative contraindications for CNB, COVID-19 patients might present with lymphopenia and cardinal manifestations of sepsis may not be seen. CNB, central neuraxial block; CO, cardiac output; ECMO, extra corporeal membrane oxygenation; GA, general anesthesia; POCUS, point of care ultrasound that includes transthoracic echocardiography (TTE), lung ultrasound and IVC scan for volume status; PNB, peripheral nerve block; SpO2-percentage oxygen saturation of hemoglobin; SVR, systemic vascular resistance when measured by non-invasive pulse contour analysis through peripheral arterial pressure.